1. Volume 71, Issue 2, Pages 281-289 (February 2017)
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) 
Andrea Necchi, Guru Sonpavde, Salvatore Lo Vullo, Daniele Giardiello, Aristotelis Bamias, Simon J. Crabb, Lauren C. Harshman, Joaquim Bellmunt, Ugo De Giorgi, Cora N. Sternberg, Linda Cerbone, Sylvain Ladoire, Yu-Ning Wong, Evan Y. Yu, Simon Chowdhury, Gunter Niegisch, Sandy Srinivas, Ulka N. Vaishampayan, Sumanta K. Pal, Neeraj Agarwal, Ajjai Alva, Jack Baniel, Ali-Reza Golshayan, Rafael Morales-Barrera, Daniel W. Bowles, Matthew I. Milowsky, Christine Theodore, Dominik R. Berthold, Gedske Daugaard, Srikala S. Sridhar, Thomas Powles, Jonathan E. Rosenberg, Matthew D. Galsky, Luigi Mariani 
European Urology 
Volume 71, Issue 2, Pages (February 2017)
DOI: /j.eururo
Copyright © 2016 European Association of Urology Terms and Conditions

2. Fig. 1
Study flow chart, with counts and reasons for patient selection.
RISC=Retrospective International Study of Invasive/Advanced Cancer of the Urothelium; UC=urothelial carcinoma.
European Urology  , DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions

3. Fig. 2
Figures showing (A) Retrospective International Study of Invasive/Advanced Cancer of the Urothelium1 (RISC1) nomogram to predict individual patient-level 1-yr, 2-yr, and 5-yr overall survival based on baseline factors before starting first-line chemotherapy. (B) Calibration plots for the validation sample of the RISC1 nomogram, estimated at 12 mo and (C) 24 mo. The average predicted probability (nomogram-predicted overall survival; x-axis) was plotted against Kaplan-Meier estimate (observed overall survival; y-axis). 95% confidence intervals of the Kaplan-Meier estimates are indicated with vertical lines. Red line indicates the reference line, indicating where an ideal nomogram would lie. (D) Decision curves for overall survival at 12 mo and (E) 24 mo applied to the RISC1 nomogram.
BMI=body-mass index; ECOG-PS=Eastern Cooperative Oncology Group Performance Status; N.A.=not available; prob.=probability; RISC=Retrospective International Study of Invasive/Advanced Cancer of the Urothelium; WBC=white blood cell count.
Legend for (D) and (E): green line: net benefit of a strategy of treating all patients; orange line: net benefit of treating no patients; dotted blue line: net benefit of a strategy of treating patients according to the nomogram predictions.
European Urology  , DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions

4. Fig. 3
Figures showing (A) Retrospective International Study of Invasive/Advanced Cancer of the Urothelium2 (RISC2) nomogram to predict individual patient-level 1-yr, 2-yr, and 5-yr overall survival based on the response to first-line chemotherapy added to the total score from RISC1. (B) Calibration plots for the validation sample of the RISC2 nomogram, estimated at 12 mo and (C) 24 mo. D) Decision curves for overall survival at 12 mo and (E) 24 mo applied to the RISC2 nomogram.
CR=complete response; CT=chemotherapy; PD=progressive disease; PR=partial response; NA=not available; RISC1=nomogram with baseline factors from the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium database; SD=stable disease.
Legend for (D) and (E): green line: net benefit of a strategy of treating all patients; orange line: net benefit of treating no patients; dotted blue line: net benefit of a strategy of treating patients according to the nomogram predictions.
European Urology  , DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions

5. European Urology 2017 71, 281-289DOI: (10.1016/j.eururo.2016.09.042)
Copyright © 2016 European Association of Urology Terms and Conditions

6. European Urology 2017 71, 281-289DOI: (10.1016/j.eururo.2016.09.042)
Copyright © 2016 European Association of Urology Terms and Conditions

7. European Urology 2017 71, 281-289DOI: (10.1016/j.eururo.2016.09.042)
Copyright © 2016 European Association of Urology Terms and Conditions

8. European Urology 2017 71, 281-289DOI: (10.1016/j.eururo.2016.09.042)
Copyright © 2016 European Association of Urology Terms and Conditions